GlassScriptPhysician profile
Bryan D Leatherman
NPI 1154367738
$21,309.28
in general payments reported to CMS, 2019-2025
11 companies · $18K in 2025
The $18K reported for 2025 was more than what 92% of Otolaryngic Allergy providers received nationally (typical 2025 total: $449).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.17 · 2020: $62.07 · 2021: $243 · 2022: $396 · 2023: $1,758 · 2024: $378 · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Consulting Fee: $5,476 · Food and Beverage: $1,779 · Travel and Lodging: $1,221 · Education: $480.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,600.00 |
| Consulting Fee | $5,476.00 |
| Food and Beverage | $1,778.93 |
| Travel and Lodging | $1,220.80 |
| Education | $480.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $18,193.41 | 2024-2025 | Tezspire, Fasenra |
| Genzyme Corporation | $1,916.18 | 2021-2025 | |
| Glaxosmithkline, LLC. | $324.97 | 2021-2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $313.39 | 2022-2025 | Dupixent |
| Optinose US, INC. | $199.76 | 2019-2024 | |
| Aerin Medical INC. | $124.63 | 2022-2025 | |
| Stryker Corporation | $78.60 | 2019-2022 | |
| Alk-Abello, INC | $51.59 | 2019-2021 | |
| Intersect Ent, INC. | $40.76 | 2021 | |
| Acclarent, INC | $35.42 | 2020-2023 | Relieva Spinplus |
| Medtronic, INC. | $30.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Leatherman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.